Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

oldgeorgestilllaughing 3 posts  |  Last Activity: Apr 22, 2015 9:59 AM Member since: Jan 1, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Travis Brown published the reasons he believes this is a buy. Interesting read on the patent situation.

    Sentiment: Strong Buy

  • Reply to

    Impact of USPTO Decision on PPS?

    by mrb1onde Mar 23, 2015 7:22 PM
    oldgeorgestilllaughing oldgeorgestilllaughing Mar 25, 2015 1:50 PM Flag

    If you google Top Picks Euro Pacific Canada, the Canadian analyst Doug Loe has Neptune as a top pick for 2015 with a $7.50 PPS. The key though is to review each component of his analysis to see what you believe. Personally this is also my #1 bet in my IRA but I think he is optimistic. I don't believe we will see much action until the earnings begin to show the impact of the new plant. I will check back in a few months, no reason to sit around and watch the paint dry.

    Sentiment: Strong Buy

  • Hi team, so you are clear where I stand, this is my #1 investment for 2015. I recently retired and live off my investment income.(hopefully). I followed George Haywood from Sarepta to this stock. No pumping, just trying to make a living. :)

    The Euro Pacific Canada analyst Doug Loe wrote this up as a 'top pick' for 2015 and here's what he had to say about the patent.
    "Neptune’s US patents can potentially be a sizable profitability driver, but clear risk
    to our patent royalty revenue until patent re-review concludes this quarter. While
    on the subject of Neptune’s IP estate, we maintain our view that this patent, which
    described medical uses for marine-derived omega-3 phospholipid esters, could
    certainly stand up to further USPTO scrutiny if only because the Office clearly
    believed at the time of original issuance that the claims therein were sufficiently
    novel and non-obvious to support patentability. Furthermore, both Aker and
    Enzymotec were sufficiently cautious on Neptune’s IP strength that they chose to
    settle on the International Trade Commission investigation previously requested by
    Neptune back in 2013, rather than to allow the investigation to proceed to
    resolution"

    Makes sense to me. GLTA

    Sentiment: Strong Buy

SRPT
12.73+0.53(+4.30%)May 1 4:00 PMEDT